Literature DB >> 31700511

NOACs in Anesthesiology.

Donat R Spahn1, Jürg-Hans Beer2, Alain Borgeat3, Pierre-Guy Chassot4, Christian Kern5, François Mach6, Krassen Nedeltchev7, Wolfgang Korte8.   

Abstract

BACKGROUND: Due to increasing use of new oral anticoagulants (NOACs), clinicians are faced more and more frequently with clinical issues related to these drugs.
OBJECTIVE: The objective of this publication is to make practical suggestions for the perioperative management of NOACs as well as for their handling in overdoses and bleedings. RECOMMENDATIONS: In elective surgery and creatinine clearance ≥ 50 ml/min, a NOAC should be discontinued 24-36 h before the intervention, and even earlier in case of reduced kidney function. In emergency interventions that cannot be delayed, the management is dependent on the NOAC plasma levels. With levels ≤ 30 ng/ml, surgery can be performed. With levels >30 ng/ml, reversal agents should be considered. In low bleeding risk surgery, NOACs can be re-started 24 h after the intervention, which is prolonged to 48-72 h after surgery with high bleeding risk. In case of NOAC overdose and minor bleedings, temporary discontinuation and supportive care are usually sufficient to control the situation. In severe or life-threatening bleedings, nonspecific and specific reversal agents should be considered.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Anesthesiology; Direct oral anticoagulants; New oral anticoagulants; Thrombin inhibitor; Xa antagonist

Year:  2019        PMID: 31700511      PMCID: PMC6739714          DOI: 10.1159/000491400

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  51 in total

1.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

Review 2.  [Direct oral anticoagulants and drug-drug interactions].

Authors:  Lukas Graf; Wolfgang Korte
Journal:  Ther Umsch       Date:  2015-02

Review 3.  Drug and dietary interactions of the new and emerging oral anticoagulants.

Authors:  J M Walenga; C Adiguzel
Journal:  Int J Clin Pract       Date:  2010-06       Impact factor: 2.503

4.  Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.

Authors:  Pierre Sié; Charles M Samama; Anne Godier; Nadia Rosencher; Annick Steib; Juan V Llau; Philippe Van der Linden; Gilles Pernod; Thomas Lecompte; Isabelle Gouin-Thibault; Pierre Albaladejo
Journal:  Arch Cardiovasc Dis       Date:  2011-10-29       Impact factor: 2.340

5.  Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

Authors:  A Hillarp; F Baghaei; I Fagerberg Blixter; K M Gustafsson; L Stigendal; M Sten-Linder; K Strandberg; T L Lindahl
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

6.  Anticoagulant and Antiplatelet Management for Spinal Procedures: A Prospective, Descriptive Study and Interpretation of Guidelines.

Authors:  Bradly S Goodman; L McLean House; Sridhar Vallabhaneni; Srinivas Mallempati; Matthew R Willey; Matthew Thomas Smith
Journal:  Pain Med       Date:  2017-07-01       Impact factor: 3.750

7.  Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study.

Authors:  Anne Godier; Anne-Sophie Dincq; Anne-Céline Martin; Adrian Radu; Isabelle Leblanc; Marion Antona; Marc Vasse; Jean-Louis Golmard; François Mullier; Isabelle Gouin-Thibault
Journal:  Eur Heart J       Date:  2017-08-14       Impact factor: 29.983

Review 8.  When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Authors:  J H Levy; W Ageno; N C Chan; M Crowther; P Verhamme; J I Weitz
Journal:  J Thromb Haemost       Date:  2016-02-17       Impact factor: 5.824

Review 9.  Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA).

Authors:  Tomas Salmonson; Jean-Michel Dogné; Heidi Janssen; Juan Garcia Burgos; Paul Blake
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2016-12-25

Review 10.  Practical management of new oral anticoagulants after total hip or total knee arthroplasty.

Authors:  W Klauser; M Dütsch
Journal:  Musculoskelet Surg       Date:  2013-11-19
View more
  2 in total

1.  Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry.

Authors:  Raquel Ferrandis; Juan V Llau; Javier F Sanz; Concepción M Cassinello; Óscar González-Larrocha; Salomé M Matoses; Vanessa Suárez; Patricia Guilabert; Luís-Miguel Torres; Esperanza Fernández-Bañuls; Consuelo García-Cebrián; Pilar Sierra; Marta Barquero; Nuria Montón; Cristina Martínez-Escribano; Manuel Llácer; Aurelio Gómez-Luque; Julia Martín; Francisco Hidalgo; Gabriel Yanes; Rubén Rodríguez; Beatriz Castaño; Elena Duro; Blanca Tapia; Antoni Pérez; Ángeles M Villanueva; Juan-Carlos Álvarez; Sergi Sabaté
Journal:  TH Open       Date:  2020-06-26

Review 2.  Preoperative Assessment of Geriatric Patients Undergoing Elective Intracranial Surgery.

Authors:  Abdullah Naji; Gabriel B Stolin; Abdelwahab Ahmed; Jason Gatling
Journal:  Cureus       Date:  2020-12-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.